593 results for "krytan tek side effects"

Search for:

Date Range to

593 Results on GlaucomaToday.com

April 2016April 2016

The Literature By Alex S. Huang, MD, PhD, and Alan T. Begian

What Is the Real IOP? How laboratory glaucoma studies may help us better understand this clinical dilemma.
By Nathan Radcliffe, MD

Screening the Future By Avni Shah, MD

Why I Perform Research in a Clinical Practice Participating in clinical research provides new options for my patients and growth opportunities for my practice.
By Gregory D. Parkhurst, MD

Highlights of the AGS Annual Meeting The latest research findings from the 26th annual meeting of the American Glaucoma Society, held March 3 to 6, 2016, in Fort Lauderdale, Florida.
By Geoffrey T. Emerick, MD

Rho Kinase/Norepinephrine Transporter Inhibition for the Treatment of Glaucoma and Ocular Hypertension An update on the clinical development of a new class of drugs.
By Jason Bacharach, MD

Tools of the Tube Trade By Jonathan S. Myers, MD

February 2016February 2016

The Literature By Andrew Garcia, MD, and Christopher C. Teng, MD

Addressing Poor Adherence By Larissa Habib, MD

Is the Grass Really Greener on the Other Side? The pros and cons of ophthalmology business models.
By Richard A. Lehrer, MD

Dealing With Reimbursement Cuts Two surgeons share their strategies.
By Paul F. Palmberg, MD, PhD, and Jeffrey A. Kammer, MD

Benchmarking and the Power of No Focus, not multitasking, is needed.
By Sean Rochelle

Update on Sustained-Release Drug Therapies These therapies have the potential to change the glaucoma treatment paradigm.
By Jonathan S. Myers, MD, and Scott J. Fudemberg, MD

S or C Corporation? Maximize tax deductions by using both.
By Carole C. Foos, CPA, and David B. Mandell, JD, MBA

Industry News

SIGS: a Simple Surgical Approach to Trabeculectomy By Yuri McKee, MD

December 2015December 2015

Lose the Cape By Steven D. Vold, MD, Chief Medical Editor

The Literature By Paul Lee, MD

Outflow Resistance Implications for canal-based surgery.
By Haiyan Gong, MD, PhD

Ab Interno Canaloplasty A minimally invasive and maximally effective glaucoma treatment.
By Mahmood A. Khaimi, MD

Advances in Ophthalmologic Imaging The current state of optical coherence tomography in glaucoma and the technology’s future applications.
By Scott Butikofer, MD; Kevin Pikey, DO; and Rohit Krishna, MD

The Phase 3 Pipeline Glaucoma drugs in the works.
By Douglas J. Rhee, MD, and Emily Ahadizadeh, BS

Sidebar: My Experience With a Dual-Blade Device By Leonard K. Seibold, MD

Glaucoma Research in India Although Indian ophthalmologists author many studies, the sheer volume of patients in the face of limited resources challenges most clinicians’ ability to devote much time to research.
By Subhabrata Chakrabarti, PhD, and Chandra S. Garudadri, MD

Industry News and Innovations

October 2015October 2015

Risk Factors in Glaucomatous Progression IOP remains the only modifiable risk factor, but fixed, historic risk factors may help clinicians set the initial target pressure and the length of follow-up intervals.
By Ta Chen Peter Chang, MD, and Elizabeth A. Hodapp, MD

Assessing Imaging Progression By analyzing the thickness of the retinal nerve fiber layer, optical coherence tomography detects and quantifies glaucomatous progression.
By Murray Fingeret, OD

Setting Target Pressures Aim for a range instead of a number to more fully account for each patient’s needs.
By Inder Paul Singh, MD

Monitoring Patients With Advanced Glaucoma Because they are at high risk of disease progression and blindness, these individuals require special attention.
By Darrell WuDunn, MD, PhD

Designing a Clinical Trial for Glaucoma Treatments Which endpoints should be used?
By Michael Waisbourd, MD; Lisa A. Hark, PhD, RD; and L. Jay Katz, MD

Determining Factors in Intensifying Glaucoma Management Take the whole patient into account.
By Kelly W. Muir, MD, MHSc

Adding Insult to Injury The contribution of systemic medication to dry eye disease.
By Sejal R. Amin, MD, and Christopher T. Hood, MD

Q&A With Glaukos CEO Thomas Burns The process of validating a new category in glaucoma and transitioning from a startup to a public company.MD
By Stephen Daily, Executive Editor, News, BMC

The Literature By Benjamin Abramowitz, MD, and Nisha Chadha, MD

Cochlin as a Glaucoma Molecular Biomarker Research may allow clinicians to initiate treatment before the disease damages patients’ optic nerves and visual fields.
By Sanjoy K. Bhattacharya, M Tech, PhD, and Richard K. Lee, MD, PhD

August 2015August 2015

Pupillary Expansion A valuable ally for cataract extraction in glaucoma patients.
By Albert S. Khouri, MD

Integrating Research Into a Busy Clinical Practice A discussion of the potential benefits and tips for getting started.
By George R. Reiss, MD

Generic Versus Branded Glaucoma Drugs Generic medications offer therapeutic benefits for some patients.
By Marcos Reyes, MD, and Lauren Wiggins, MD

Glaucoma Drugs in the Pipeline Physicians share which coming therapies they are most eager to use in their practices.
By Malik Y. Kahook, MD; Paul L. Kaufman, MD; Robert J. Noecker, MD, MBA; and Nathan M. Radcliffe, MD

June 2015June 2015

The Literature By Kevin Kaplowitz, MD, and Osamah Saeedi, MD

123456789101112131415 | Next >